Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
July 1, 2023
Stefano Delli Pizzi, Piero Chiacchiaretta, Carlo Sestieri et al.
18 citations
Lysergic acid diethylamide (LSD) is an atypical psychedelic compound that exerts its effects through pleiotropic actions, mainly involving 1A/2A serotoninergic (5-HT) receptor subtypes. However, the mechanisms by which LSD promotes a reorganization of the brain's functional activity and connectivity are still partially unknown. Our study analyzed resting-state functional magnetic resonance...
Psychopharmacology
July 1, 2023
Iga Adamska, Karolina Finc
8 citations
Psychedelics are getting closer to being widely used in clinical treatment. Music is known as a key element of psychedelic-assisted therapy due to its psychological effects, specifically on the emotion, meaning-making, and sensory processing. However, there is still a lack of understanding in how psychedelics influence brain activity in experimental settings involving music listening. The main...
June 9, 2023
Mika Turkia
2 citations
preprint
This retrospective study presents the case of a young woman in her mid-twenties who suffered from insecurity and abandonment-related anxiety, which intensified after a breakup of her relationship. Her parents' alcoholism and schizophrenia, as well as emotional and physical violence, had been a part of her childhood, but they had appeared 'normal' to her. Her parents and relatives had not...
Addiction
June 7, 2023
Katherine M Keyes, Megan E. Patrick
42 citations
Abstract Background and aims Given the shifting landscape of hallucinogen use, particularly with increased therapeutic use, understanding current changes in use is a necessary part of examining the potential risk hallucinogens pose to vulnerable populations, such as young adults. This study aimed to measure hallucinogen use among young adults aged 19–30 years from 2018 to 2021. Design, setting...
Peer Review
June 3, 2023
Matheus Antônio Garcia Marson, João Vicente de Paiva Neto, Jayne Zaniratto et al.
A dietilamida do ácido lisérgico (LSD) é uma droga proibida mundialmente, contudo diversos estudos sugerem haver uma variedade de possíveis aplicações terapêuticas e benefícios no tratamento de ansiedade, depressão e abuso de substâncias, além de propriedades nootrópicas. O estudo teve como objetivo verificar aplicações terapêuticas, efeitos relevantes à saúde mental e segurança do LSD como...
medRxiv
June 1, 2023
Andreas Halman, Geraldine Kong, Jerome Sarris et al.
17 citations
preprint
Abstract Classic psychedelics, lysergic acid diethylamide, psilocybin, mescaline and N,N-dimethyltryptamine, are potent psychoactive substances that have been studied for their physiological and psychological effects. However, our understanding of the potential interactions and outcomes of using these substances are used in combination with other psychoactive drugs is limited. This systematic...
Neuroimage
June 1, 2023
Rui Dai, Tony E. Larkin, Zirui Huang et al.
49 citations
The neurobiology of the psychedelic experience is not fully understood. Identifying common brain network changes induced by both classical (i.e., acting at the 5-HT2 receptor) and non-classical psychedelics would provide mechanistic insight into state-specific characteristics. We analyzed whole-brain functional connectivity based on resting-state fMRI data in humans, acquired before and during...
Psychiatric Clinics of North America
June 1, 2023
Shubham Kamal, Manish Kumar Jha, Rajiv Radhakrishnan
32 citations
There is increasing interest in exploring the therapeutic potential of psychedelics in treatment-resistant depression (TRD). Classic psychedelics (such as psilocybin, LSD, ayahuasca/DMT), and atypical psychedelics (such as ketamine) have been studied in TRD. The evidence for the classic psychedelics TRD is limited at the present time; early studies however show promising results. There is also...
World Journal of Psychiatry
May 19, 2023
Lakshan N Fonseka, Benjamin K.p. Woo
12 citations
With the Food and Drug Administration designation in 2017 of 3,4-methylenedioxymethamphetamine (MDMA) as a breakthrough therapy in post-traumatic stress disorder and psilocybin in treatment-resistant depression, psychedelic drugs have continued to garner the attention of researchers and clinicians for their promise of unmatched, rapid improvement in a multitude of psychiatric conditions....
ACS Chemical Neuroscience
May 17, 2023
Khalyd J Clay, Ava E Axelrod, Christina M MacLaughlin et al.
2 citations
Several naturally occurring molecules exhibit unique potential in treating certain elements of psychiatric illnesses and are being actively pursued in therapeutic development. Among these are molecules termed entheogens, a preferred name for plant-derived compounds that alter human consciousness for religious or spiritual purposes, which are especially important to various Indigenous groups,...
Australian Journal of Chemistry
May 16, 2023
Eliza Milliken, Peter Galettis, Jenny Martin
4 citations
Classic psychedelics such as psilocybin, ketamine and lysergic acid diethylamide (LSD) are 5HT2A serotonin receptor agonists that produce individualised subjective affects. Today, public interest in psychedelic medicine has reached a fervour but the evidence for clinical benefit still lags. Psilocybin and psilocin are tryptophan based alkaloids found worldwide in mushrooms of the genera...
bioRxiv (Cold Spring Harbor Laboratory)
May 12, 2023
S. Parker Singleton, Christopher Timmermann, Andrea I. Luppi et al.
18 citations
preprint
Psychedelics offer a profound window into the functioning of the human brain and mind through their robust acute effects on perception, subjective experience, and brain activity patterns. In recent work using a receptor-informed network control theory framework, we demonstrated that the serotonergic psychedelics lysergic acid diethylamide (LSD) and psilocybin flatten the brain's control energy...
Journal of Forensic Sciences
May 1, 2023
Shu-Hua Zhang, Angeline S Y Tang, Reenie S L Chin et al.
7 citations
With the emergence of new psychoactive substances (NPSs) over the years, the substances detected on stamps (also known as blotter papers) have also evolved from the traditional drug-lysergic acid diethylamide (LSD) to the multiple variants of lysergamides such as ALD-52 and 1P-LSD. The analysis of such blotter papers is usually done by solvent extraction followed by identification using gas...
International Journal of Advanced Research
April 30, 2023
Dimple Gupta, Chirag Ambaliya, Aman Ankur et al.
Background:Classical psychedelics are a group of drugs which act as agonists on the serotonin-2A (5-HT2A) receptor. Evidence suggests they may have a uniquely rapid and enduring positive effect on mood. However, marked heterogeneity between methodological designs in this emerging field remains a significant concern. Aims:To determine how differences in the type of psychedelic agent used and the...
Neuropsychopharmacology
April 25, 2023
Peter Bedford, Daniel J. Hauke, Zheng Wang et al.
43 citations
Abstract Psychedelics have emerged as promising candidate treatments for various psychiatric conditions, and given their clinical potential, there is a need to identify biomarkers that underlie their effects. Here, we investigate the neural mechanisms of lysergic acid diethylamide (LSD) using regression dynamic causal modelling (rDCM), a novel technique that assesses whole-brain effective...
Psychotropes
April 21, 2023
Pierre Poloméni
Les adolescents et jeunes adultes participant à des événements musicaux consomment fréquemment des substances psychoactives pour améliorer la qualité des relations et des perceptions. Parmi ces substances, une association de LSD puis de MDMA, prises à une heure d’intervalle, dénommée Candy Flip, connue depuis longtemps, bénéficie d’une bonne réputation. Notre travail explore ces substances en...
Neuropharmacology
April 2, 2023
Farah Z Zia, Michael H. Baumann, Sean J Belouin et al.
28 citations
Chronic pain is a leading cause of disability, reduced productivity, healthcare seeking behavior, and a contributor to opioid overdose in the United States. For many people, pain can be satisfactorily managed by existing medicines and comprehensive psychosocial treatments. For others, available treatments are either ineffective or not acceptable, due to side effects and concerns about risks....
Journal of Affective Disorders
April 1, 2023
Otto Simonsson, Peter S. Hendricks, Richard Chambers et al.
124 citations
Previous studies have investigated challenging, difficult, or distressing classic psychedelic experiences, but little is known about the prevalence and associations of such experiences. Using nationally representative data of the US adult population (N = 2822), this study examined the prevalence and associations of challenging, difficult, or distressing experiences using classic psychedelics,...
Canadian journal of health history = Revue canadienne d'histoire de la sante
April 1, 2023
Andrew Jones
2 citations
In 1962, Ontario's Addiction Research Foundation launched the first double-blind randomized controlled trial of LSD therapy as a treatment for alcoholism. The study, which found that LSD was not effective, was heavily criticized by other therapists working with the drug. These critics argued that the Toronto researchers who carried out the study were biased against LSD and used an...
Mindfulness
April 1, 2023
Charlotta Simonsson, Richard Chambers, Peter S. Hendricks et al.
15 citations
Previous research has investigated potential synergies between classic psychedelics and meditation practice, but relatively little remains known about the relationship between classic psychedelic experiences and engagement with meditation practice.The purpose of this study was to investigate associations between classic psychedelic experiences and engagement with two popular types of...